Print Page  Close Window
Investor Overview

NASDAQ CM | IDXG (Common Stock)

$0.45

  0.00 (0.00%)

Volume0

May 04, 2016  3:59 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.

Company Overview

Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has three commercialized molecular tests; PancraGen for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay. Interpace Diagnostics mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science.

Webcasts

November 12, 2015 4:30 p.m. ET

Events and Presentations

Primary IR Contact

Doug Sherk
EVC Group

Phone: (415) 652-9100

Email: dsherk@evcgroup.com